These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9248972)

  • 1. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
    Wilson WR; Bouza E; Lode H; Mouton Y
    J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia.
    Ko WC; Lee HC; Chuang YC; Liu CC; Wu JJ
    J Infect; 2000 May; 40(3):267-73. PubMed ID: 10908022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
    Dulaney Lopez AM; Rodriguez JC; Lopez-Samblas AM; Estes KS
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cefotaxime in sequential therapy of community acquired pneumonia].
    Wolska-Goszka L; Petlak A; Słomiński JM
    Pol Merkur Lekarski; 1999 Sep; 7(39):99-101. PubMed ID: 10598482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of antibacterial drugs.
    Med Lett Drugs Ther; 1998 Mar; 40(1023):33-42. PubMed ID: 9549552
    [No Abstract]   [Full Text] [Related]  

  • 6. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of cefotaxime against infections (author's transl)].
    Lepeu G; Bertrand A; Armengaud M; Aubertin J
    Nouv Presse Med; 1981 Feb; 10(8):594-7. PubMed ID: 6259600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical trial of a new broad-spectrum cephalosporin: HR 756 (cefotaxime)].
    Poletti T; Bertola D; Pellerito R; Soragna A
    Minerva Med; 1980 Jul; 71(27):1935-43. PubMed ID: 6248823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical use of new cephalosporins for severe infections in internal medicine].
    Stille W
    Wien Klin Wochenschr Suppl; 1983; 142():18-20. PubMed ID: 6316668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefotaxime in healthy volunteers and patients.
    Patel KB; Nicolau DP; Nightingale CH; Quintiliani R
    Diagn Microbiol Infect Dis; 1995; 22(1-2):49-55. PubMed ID: 7587050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cefotaxime in bronchopulmonary infections (author's transl)].
    Kermarec J; Sauvaget J
    Nouv Presse Med; 1981 Feb; 10(8):650-3. PubMed ID: 6259612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
    García-Contreras F; Del-Angel-García G; Ramírez Cuenca A; Malváez-Valdes M; Vega Yáñez A; Amato D
    Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cefotaxime in the treatment of severe infections due to multiresistant Gram-negative bacilli (author's transl)].
    Clumeck N; Van Laethem Y; Vanhoof R; Jaspar N; George G; Rapin M; Butzler JP
    Nouv Presse Med; 1981 Feb; 10(8):622-4. PubMed ID: 6259606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefotaxime in the treatment of prophylaxis of surgical infections.
    Wittmann DH; Jones RN; Malledant J; Privitera G
    J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime.
    Turnidge JD
    Diagn Microbiol Infect Dis; 1995; 22(1-2):57-69. PubMed ID: 7587052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic aspects of antibacterial treatment with cefotaxime.
    Cooke J; Doreau C; Eandi M
    J Chemother; 1997 May; 9 Suppl 2():34-45. PubMed ID: 9248974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of cefotaxime at various dosage levels in urinary tract infections (author's transl)].
    Guibert J; Acar JF; Justin C; Kitzis MD
    Nouv Presse Med; 1981 Feb; 10(8):625-7. PubMed ID: 6259607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.